FDA 483 - Samsung Biologics Co., Ltd.
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
Samsung BioLogics Co., Ltd. in Incheon, Republic of Korea, was inspected for drug substance and drug product manufacturing, revealing significant deficiencies across multiple areas. Issues included compromised HEPA filter integrity, inadequate aseptic techniques, and deficiencies in environmental monitoring and equipment maintenance. Furthermore, the firm exhibited poor control over deviations, CAPA effectiveness, laboratory testing procedures, and process monitoring, indicating a systemic lack of assurance in product quality and compliance.
- Company
- Samsung Biologics Co., Ltd.
- Product Type
- Drugs
ID · e6eee8b1-6875-48d5-b66c-78c440f4dc88